<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036816</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-18001 -88001</org_study_id>
    <secondary_id>EORTC-18001</secondary_id>
    <secondary_id>EORTC-88001</secondary_id>
    <nct_id>NCT00036816</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Melanoma of the Eye</brief_title>
  <official_title>Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells and&#xD;
      decrease the recurrence of melanoma of the eye.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of vaccine therapy in&#xD;
      treating patients who are at high risk for recurrent melanoma of the eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether adjuvant NA17-A and melanoma differentiation peptides are effective in&#xD;
           decreasing the occurrence of liver metastasis in HLA-A2-positive patients with primary&#xD;
           ocular melanoma at high risk of relapse.&#xD;
&#xD;
        -  Determine whether this regimen increases survival of these patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor&#xD;
      size (medium vs large), prior treatment of primary tumor (surgery vs radiotherapy), and&#xD;
      participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive vaccination with NA17-A and melanoma differentiation peptides&#xD;
           (e.g., tyrosinase, Melan-A, and gp100 antigens) subcutaneously and intradermally on days&#xD;
           1, 8, 15, and 22. Patients then receive a vaccination once every 14 days for 4 doses,&#xD;
           once every 28 days for 4 doses, once every 56 days for 4 doses, and then once every 3&#xD;
           months for a total of 4 years.&#xD;
&#xD;
        -  Arm II: Patients undergo observation only every 3 months for 2 years and then every 6&#xD;
           months for 2 years.&#xD;
&#xD;
      All patients are followed every 3 months for 1 year and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 600 patients (300 per treatment arm) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">13</enrollment>
  <condition>Intraocular Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NA17-A antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of ocular melanoma&#xD;
&#xD;
               -  No melanoma of the iris&#xD;
&#xD;
          -  Disease adequately treated by prior surgery (enucleation or tumorectomy) and/or&#xD;
             radiotherapy&#xD;
&#xD;
               -  No more than 5 weeks since the beginning of primary tumor treatment&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 12.0 mm in largest diameter OR&#xD;
&#xD;
               -  At least 6.0 mm in height&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count at least 700/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Lactate dehydrogenase no greater than 2 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN&#xD;
&#xD;
          -  Gamma glutamyl transpeptidases no greater than 2 times ULN&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
          -  Hepatitis B antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  No clinical immunodeficiency&#xD;
&#xD;
          -  No autoimmune diseases&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No multiple sclerosis&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy except surgically cured carcinoma in situ of the cervix or basal&#xD;
             cell or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical conditions that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No other concurrent immunotherapy or biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior steroids&#xD;
&#xD;
          -  No concurrent chronic therapy with high doses of corticosteroids (e.g.,&#xD;
             methylprednisolone at least 12 mg/day)&#xD;
&#xD;
          -  Concurrent topical or inhalation steroids allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior proton beam therapy allowed&#xD;
&#xD;
          -  Prior brachytherapy without tumor resection allowed&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the spleen&#xD;
&#xD;
          -  No prior pre-enucleation radiotherapy&#xD;
&#xD;
          -  No prior ruthenium Ru 106 as primary therapy alone&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior transcleral tumor resection allowed&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No prior major organ allograft&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent systemic immunosuppressive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Brichard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan U. Prause, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

